Fed. Circ. Applies Teva Deference In 2 Types Of Cases

Law360 (May 16, 2018, 1:53 PM EDT) -- Over three years have now passed since the U.S. Supreme Court’s decision in Teva Pharmaceuticals USA Inc. v. Sandoz Inc. changed the standard of review for factual findings made in the course of claim construction.[1] The court, of course, after some 20 years of contrary Federal Circuit practice and precedent, held that courts must now review such fact determinations not under the de novo standard generally applicable to claim construction, but under the deferential “clear error” standard pursuant to Federal Rule of Civil Procedure 52(a).[2]

The first post-Teva case — In re Papst Licensing Digital Camera Patent Litigation — did not...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!